In Brief This Week: Beckman Coulter, FDA; Siemens, Janssen Pharmaceutica; AMP, FASEB; Broad Institute, Agilent; More | GenomeWeb

NEW YORK (GenomeWeb News) – The US Food and Drug Administration this week gave 510(k) clearance to Beckman Coulter's Access AccuTnl+3 troponin l assay for use on the company's Access 2 immunoassay system.

In order to gain the long-awaited clearance, Beckman Coulter conducted a prospective clinical trial for the assay that included the enrollment of more than 1,900 subjects, following guidance from FDA in 2010 that manufacturers of troponin assays modernize the performance evaluation and regulatory review of such tests, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.